Don’t Let Recent momentum Confuse Your Outlook on Catabasis Pharmaceuticals Inc. [CATB]

Catabasis Pharmaceuticals Inc. [CATB] stock is down -8.37 while the S&P 500 has risen 0.14% on Wednesday, 12/02/20. While at the time of this article, CATB ATR is sitting at 0.32, with the beta value at 2.02. This stock’s volatility for the past week remained at 23.85%, while it was 10.59% for the past 30-day period. CATB has fallen -$0.18 from the previous closing price of $2.09 on volume of 10.15 million shares.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


On 12, November 2020, Catabasis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides a Corporate Update. According to news published on Yahoo Finance, — Cash and Cash Equivalents Totaled $52.9 Million as of September 30, 2020 –.

Analyst Birdseye View:

The most recent analyst activity for Catabasis Pharmaceuticals Inc. [NASDAQ:CATB] stock was on October 27, 2020, when it was Downgrade with a Perform rating from Oppenheimer. On October 27, 2020, H.C. Wainwright Downgrade a Neutral rating. On October 01, 2020, H.C. Wainwright Initiated a Buy rating and increased its price target to $24. On October 05, 2017, Oppenheimer Reiterated an Outperform rating and increased its price target to $7. On February 02, 2017, Citigroup Downgrade a Neutral rating. On December 22, 2016, H.C. Wainwright Initiated a Buy rating and boosted its target amount on this stock to $14. On June 08, 2016, Wedbush Reiterated an Outperform rating and improved its amount target to $17.

In the past 52 weeks of trading, this stock has oscillated between a low of $1.25 and a peak of $8.59. Right now, according to Wall Street analyst the average 12-month amount target is $24.00. At the most recent market close, shares of Catabasis Pharmaceuticals Inc. [NASDAQ:CATB] were valued at $1.91.


The Principal structure of this organization shows its whole liability to whole principal at 5.93 and the whole liability to whole assets at 5.39. It shows enduring liability to the whole principal at 2.71 and enduring liability to assets at 0.02 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 1.48 points at 1st support level, the second support level is making up to 0.88. But as of 1st resistance point, this stock is sitting at 2.97 and at 3.86 for 2nd resistance point.

Catabasis Pharmaceuticals Inc. [CATB] reported its earnings at -$0.56 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.51/share signifying the difference of -0.05 and -9.80% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.53 calling estimates for -$0.45/share with the difference of -0.08 depicting the surprise of -17.80%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Catabasis Pharmaceuticals Inc. [NASDAQ:CATB] is 8.00. Likewise, the Quick ratio is also the same, showing Cash ratio at 7.20. Now if looking for a valuation of this stock’s amount to book ratio is 2.06.